Holen Sie sich die Stockscreener-App
78.98
0.57%
0.45
Schlusskurs vom Vortag:
$78.53
Offen:
$79.58
24-Stunden-Volumen:
2.87M
Relative Volume:
2.06
Marktkapitalisierung:
$6.55B
Einnahmen:
$1.73B
Nettoeinkommen (Verlust:
$682.64M
KGV:
10.21
EPS:
7.7364
Netto-Cashflow:
$411.18M
1W Leistung:
+5.72%
1M Leistung:
+12.59%
6M Leistung:
+5.89%
1J Leistung:
+56.61%
1-Tages-Spanne:
$78.10
$80.00
1-Wochen-Bereich:
$71.80
$80.00
52-Wochen-Spanne:
$43.17
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
78.98 | 6.55B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics Inc (PTCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance
PTC Therapeutics Inc (PTCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
PTC Therapeutics Inc (PTCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PTC Therapeutics Inc (PTCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PTC Therapeutics Inc (PTCT) Institutional Confidence - TradingKey
PTC Therapeutics Inc (PTCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PTC Therapeutics prices convertible notes for refinancing - MSN
PTC Therapeutics Inc (PTCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PTC Therapeutics Inc (PTCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
PTC Therapeutics SharesMidweek jump after recent debt refinancing - AD HOC NEWS
PTC Therapeutics Jumps 7.7% Amid Sector-Wide Rally - AlphaStreet
The Technical Signals Behind (PTCT) That Institutions Follow - Stock Traders Daily
PTC Therapeutics falls as investors weigh $500M 2031 convertible notes financing - Quiver Quantitative
PTC Therapeutics (PTCT) Launches $500M Convertible Notes Offerin - GuruFocus
PTC Therapeutics prices $500M 0% convertible notes due 2031 to refinance 2026 notes - TradingView
[8-K] PTC THERAPEUTICS, INC. Reports Material Event - Stock Titan
PTC Therapeutics Prices $500 Million Notes Offering - marketscreener.com
Biotech PTC sells $500M 0% notes at 40% premium to stock - Stock Titan
PTC Therapeutics Prices $500 Million 0% Convertible Senior Notes Due 2031 - TradingView
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes - TradingView
PTC Therapeutics Plans $500 Million Convertible Notes Offering to Refinance 2026 Notes - marketscreener.com
PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes - TradingView
PTC Therapeutics Q1 earnings call highlights - MSN
PTC Therapeutics Insider Sold Shares Worth $1,595,775, According to a Recent SEC Filing - Moomoo
PTC Therapeutics climbs after guidance hike - MSN
96,860 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Castleark Management LLC - MarketBeat
Insider Sell: Eric Pauwels Sells 21,277 Shares of PTC Therapeuti - GuruFocus
PTC Therapeutics CBO Eric Pauwels sells $1.6 million in stock - Investing.com UK
PTC Therapeutics CBO Eric Pauwels sells $1.6 million in stock By Investing.com - Investing.com South Africa
PTC Therapeutics (PTCT) CBO sells shares under 10b5-1 trading plan - Stock Titan
Sector Gamma AS Sells 56,189 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC THERAPEUTICS INC (NASDAQ:PTCT) Scores Perfect 10/10 For Technical Breakout Setup - ChartMill
PTCT News | PTC THERAPEUTICS INC (NASDAQ:PTCT) - ChartMill
Fidelity affiliate seeks to sell PTCT (NASDAQ: PTCT) 17,566 shares on 06/10/2026 - Stock Titan
PTC Therapeutics upgraded at Jefferies on Sephience - MSN
Los Angeles Capital Management LLC Has $2.46 Million Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Key facts: PTC Therapeutics director resigns; posts record revenue - TradingView
PTC Therapeutics Director Resigns, Moves to Advisory Role - TipRanks
Alethia Young resigns from PTC Board, to serve as consultant - TradingView
PTC Therapeutics (NASDAQ: PTCT) director Alethia Young shifts to consultant role - Stock Titan
PTC Therapeutics Shares Rise After Upgrade From Citigroup - Moomoo
Transcript : PTC Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 09 - marketscreener.com
PTCT Raised by Citigroup -- Price Target Increased to $108 - GuruFocus
PTC Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Citigroup Upgrades PTC Therapeutics to Buy From Hold, Raise Price Target to $108 From $76 - marketscreener.com
PTC Therapeutics (PTCT) reports Q1 loss, tops revenue estimates - MSN
19,877 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Commonwealth of Pennsylvania Public School Empls Retrmt SYS - MarketBeat
A Look At PTC Therapeutics (PTCT) Valuation As Models Flag A Potential Discount - Sahm
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):